As of August 2008, XenoTech, LLC has operated as a subsidiary of Japanese-based Sekisui Chemical Co. Ltd., Sekisui America Corporation. XenoTech is organized around drug metabolism and pharmacokinetics products to include hepatocytes that are used in drug discovery and preclinical drug development to perform experiments requiring intact cellular systems; subcellular fractions that are used in drug discovery and preclinical drug development to evaluate the in vitro metabolism of drug candidates; and Kupffer Cells, which are macrophages endogenous to the liver and modulate hepatic inflammation and injury associated with various pathophysiologies and toxicities. The company also features media and reagents products designed for use in in-vitro ADME studies; recombinant enzymes products used to support drug discovery and preclinical drug development services; P450 substrates and metabolites that are used in early-stage drug discovery services; and custom products. In addition, it distributes Cypex's Bactosomes, cytochrome P450 substrates and metabolites, in North America; and offers analytical, biologic, and consulting services, as well as drug metabolism and transporters, and enzyme induction and inhibition, in vivo ADME, lysosomal trapping, and pharmacology services. The company markets its products through a network of distributors in Japan, Europe, India, Singapore, China, South Korea, Africa, and Taiwan. XenoTech, LLC has a strategic alliance with XenoGesis.